Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dapirolizumab pegol - Biogen/UCB

Drug Profile

Dapirolizumab pegol - Biogen/UCB

Alternative Names: Anti-CD40L Fab; Anti-CD40L Fab-PEG; CD40L - Fab; CDP-7657; Peg-dapirolizumab; Pegylated anti-CD40L antibody

Latest Information Update: 22 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec; UCB
  • Developer Biogen; UCB
  • Class Antibodies; Antirheumatics; Fab fragments; Monoclonal antibodies; Polyethylene glycols
  • Mechanism of Action CD40 ligand inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Systemic lupus erythematosus
  • No development reported Amyotrophic lateral sclerosis; Rheumatoid arthritis

Most Recent Events

  • 24 Jul 2019 UCB in collaboration with Biogen plans to initiate a phase III trial for Systemic lupus erythematosus (SLE) in the first half of 2020.
  • 12 Jun 2019 Interim efficacy, adverse events and pharmacodynamics data from a phase IIb trial in systemic lupus erythematosus were presented at the 20th Annual Congress of the European League Against Rheumatism (EULAR-2019)
  • 15 Nov 2018 UCB completes a phase II trial in Systemic lupus erythematosus (Adjunctive treatment) in USA, Bulgaria, Germany, Hungary, Spain, Ukraine, Russia, Romania, Poland, Peru, Mexico, Colombia, Chile (IV) (NCT02804763)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top